Today, the screening of IDH1 and IDH2 mutations play an important role in the classification of AML and for setting ab initio as the most effective treatment, even due to the recent availability of IDH1 and IDH2 inhibitors (Ivosidenib and Enasidenib). This evidence concerns the gene IDH2 and acute myeloid leukemia.